secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001437749-21-026193
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma Q1 revenue down 16% to $12.8M; net income falls to $0.5M
-----------------------------------------------------------------------------

- Revenue $12.8M vs $15.2M YoY, a decrease of 16.0%.
- Operating income $0.6M vs $1.5M; net income $0.5M ($0.02 basic EPS) vs $1.0M ($0.04 basic EPS).
- Diluted EPS $0.02 vs $0.03 in the prior-year quarter.
- Two largest customers in Contract Manufacturing Segment accounted for ~91% of revenue, consistent with YoY.
- Co-CEOs cite pandemic-related safety stock and consumer demand in prior year as cause for revenue decline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774921026193/0001437749-21-026193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774921026193/inbp20211109_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-21-026193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer